Literature DB >> 25769723

The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.

Ke Chen1, Kongming Wu2, Xuanmao Jiao1, Liping Wang1, Xiaoming Ju1, Min Wang1, Gabriele Di Sante1, Shaohua Xu1, Qiong Wang1, Kevin Li1, Xin Sun1, Congwen Xu1, Zhiping Li1, Mathew C Casimiro1, Adam Ertel3, Sankar Addya3, Peter A McCue4, Michael P Lisanti4, Chenguang Wang1, Richard J Davis5, Graeme Mardon6, Richard G Pestell7.   

Abstract

Prostate cancer is the second leading form of cancer-related death in men. In a subset of prostate cancer patients, increased chemokine signaling IL8 and IL6 correlates with castrate-resistant prostate cancer (CRPC). IL8 and IL6 are produced by prostate epithelial cells and promote prostate cancer cell invasion; however, the mechanisms restraining prostate epithelial cell cytokine secretion are poorly understood. Herein, the cell-fate determinant factor DACH1 inhibited CRPC tumor growth in mice. Using Dach1(fl/fl)/Probasin-Cre bitransgenic mice, we show IL8 and IL6 secretion was altered by approximately 1,000-fold by endogenous Dach1. Endogenous Dach1 is shown to serve as a key endogenous restraint to prostate epithelial cell growth and restrains migration via CXCL signaling. DACH1 inhibited expression, transcription, and secretion of the CXCL genes (IL8 and IL6) by binding to their promoter regulatory regions in chromatin. DACH1 is thus a newly defined determinant of benign and malignant prostate epithelium cellular growth, migration, and cytokine abundance in vivo. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769723      PMCID: PMC4433595          DOI: 10.1158/0008-5472.CAN-14-0611

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  The role of hormonal treatment in prostate cancer.

Authors:  Stephan H Flüchter; Ralf Weiser; Christoph Gamper
Journal:  Recent Results Cancer Res       Date:  2007

2.  Attenuation of Forkhead signaling by the retinal determination factor DACH1.

Authors:  Jie Zhou; Chenguang Wang; Zhibin Wang; Will Dampier; Kongming Wu; Mathew C Casimiro; Iouri Chepelev; Vladimir M Popov; Andrew Quong; Aydin Tozeren; Keji Zhao; Michael P Lisanti; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  Hormonal control of androgen receptor function through SIRT1.

Authors:  Maofu Fu; Manran Liu; Anthony A Sauve; Xuanmao Jiao; Xueping Zhang; Xiaofang Wu; Michael J Powell; Tianle Yang; Wei Gu; Maria Laura Avantaggiati; Nagarajan Pattabiraman; Timothy G Pestell; Fang Wang; Andrew A Quong; Chenguang Wang; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2006-08-21       Impact factor: 4.272

4.  The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling.

Authors:  Vladimir M Popov; Jie Zhou; L Andrew Shirley; Judy Quong; Wen-Shuz Yeow; Jennifer A Wright; Kongming Wu; Hallgeir Rui; Ratna K Vadlamudi; Jie Jiang; Rakesh Kumar; Chenguang Wang; Richard G Pestell
Journal:  Cancer Res       Date:  2009-07-15       Impact factor: 12.701

5.  The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.

Authors:  Kongming Wu; Sanjay Katiyar; Agnes Witkiewicz; Anping Li; Peter McCue; Liang-Nian Song; Lifeng Tian; Ming Jin; Richard G Pestell
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  R W Veltri; M C Miller; G Zhao; A Ng; G M Marley; G L Wright; R L Vessella; D Ralph
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

7.  Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.

Authors:  Guoqing Liao; Liuh-Yow Chen; Aihua Zhang; Aparna Godavarthy; Fang Xia; Jagadish Chandra Ghosh; Hui Li; J Don Chen
Journal:  J Biol Chem       Date:  2002-11-18       Impact factor: 5.157

8.  Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8.

Authors:  Kongming Wu; Sanjay Katiyar; Anping Li; Manran Liu; Xiaoming Ju; Vladimir M Popov; Xuanmao Jiao; Michael P Lisanti; Antonella Casola; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-08       Impact factor: 11.205

9.  Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer.

Authors:  Ke Chen; Kongming Wu; Michael Gormley; Adam Ertel; Jing Wang; Wei Zhang; Jie Zhou; Gabriele Disante; Zhiping Li; Hallgeir Rui; Andrew A Quong; Steven B McMahon; Haiteng Deng; Michael P Lisanti; Chenguang Wang; Richard G Pestell
Journal:  Oncotarget       Date:  2013-06

10.  Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues.

Authors:  Daniel A Smith; Atsushi Kiba; Yang Zong; Owen N Witte
Journal:  Mol Cancer Res       Date:  2013-07-18       Impact factor: 5.852

View more
  17 in total

Review 1.  Interplay of retinal determination gene network with TGF-β signaling pathway in epithelial-mesenchymal transition.

Authors:  Yu Liu; Deguang Kong; Hua Wu; Xun Yuan; Hanxiao Xu; Cuntai Zhang; Gaosong Wu; Kongming Wu
Journal:  Stem Cell Investig       Date:  2015-06-09

2.  Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate.

Authors:  Wan-Fu Wu; Laure Maneix; Jose Insunza; Ivan Nalvarte; Per Antonson; Juha Kere; Nancy Yiu-Lin Yu; Virpi Tohonen; Shintaro Katayama; Elisabet Einarsdottir; Kaarel Krjutskov; Yu-Bing Dai; Bo Huang; Wen Su; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

3.  Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis.

Authors:  Guohui Qin; Jingyao Lian; Lan Huang; Qitai Zhao; Shasha Liu; Zhen Zhang; Xinfeng Chen; Dongli Yue; Lifeng Li; Feng Li; Lidong Wang; Viktor Umansky; Bin Zhang; Shengli Yang; Yi Zhang
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

4.  Global polysome analysis of normal and injured podocytes.

Authors:  Masahiro Okabe; Masaru Motojima; Yoichi Miyazaki; Ira Pastan; Takashi Yokoo; Taiji Matsusaka
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-31

5.  Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.

Authors:  Lale Ozcan; Devram S Ghorpade; Ze Zheng; Jane Cristina de Souza; Ke Chen; Marc Bessler; Melissa Bagloo; Beth Schrope; Richard Pestell; Ira Tabas
Journal:  Cell Rep       Date:  2016-05-26       Impact factor: 9.423

6.  Transcriptome-wide association analysis identifies DACH1 as a kidney disease risk gene that contributes to fibrosis.

Authors:  Tomohito Doke; Shizheng Huang; Chengxiang Qiu; Hongbo Liu; Yuting Guan; Hailong Hu; Ziyuan Ma; Junnan Wu; Zhen Miao; Xin Sheng; Jianfu Zhou; Aili Cao; Jianhua Li; Lewis Kaufman; Adriana Hung; Christopher D Brown; Richard Pestell; Katalin Susztak
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 19.456

7.  An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.

Authors:  Ze Zheng; Lalitha Nayak; Wei Wang; Arif Yurdagul; Xiaobo Wang; Bishuang Cai; Stephanie Lapping; Lale Ozcan; Rajasekhar Ramakrishnan; Richard G Pestell; Mukesh K Jain; Ira Tabas
Journal:  Blood       Date:  2018-12-01       Impact factor: 25.476

8.  Endogenous Dach1 in cancer.

Authors:  Kongming Wu; Xun Yuan; Richard Pestell
Journal:  Oncoscience       Date:  2015-09-23

Review 9.  The retinal determination gene network: from developmental regulator to cancer therapeutic target.

Authors:  Deguang Kong; Yu Liu; Qian Liu; Na Han; Cuntai Zhang; Richard G Pestell; Kongming Wu; Gaosong Wu
Journal:  Oncotarget       Date:  2016-08-02

10.  DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis.

Authors:  Qian Liu; Anping Li; Shengnan Yu; Shuang Qin; Na Han; Richard G Pestell; Xinwei Han; Kongming Wu
Journal:  J Hematol Oncol       Date:  2018-04-10       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.